3 Things to Watch at Merrimack

Merrimack Pharmaceuticals'  (NASDAQ: MACK  )  IPO debuted with a thud this past summer, falling 14% intraday from its $7 listing price. The biopharmaceuticals company focuses on innovative treatments for serious conditions with a primary focus on cancers. The product pipeline includes a promising lead drug and a secondary drug backed by Sanofi (NYSE: SNY  ) . But the company's trading nearly 13% below its list price.

Here are three things to watch when considering Merrimack.

1. Lead drug
MM-398 began phase 3 trials this past summer  for treatment-resistant pancreatic cancer. The Food and Drug Administration granted the drug orphan status. Additional early stage trials will examine its efficacy with colorectal cancer and gliomas -- or tumors beginning in the brain or spinal cord.

Transparency Market Research  estimates that the domestic pancreatic cancer market will hit $1.2 billion by 2015. The leading treatment has historically been Eli Lilly's (NYSE: LLY  )  chemo drug Gemzar. But a rising new wave of treatments, including Merrimack and Celgene's (NASDAQ: CELG  )  Abraxane, offers options for patients for whom Gemzar wasn't enough .

Merrimack paid up to have a chance in this market. The company acquired MM-398's original developer in 2009 . Last year, Merrimack agreed to pay up to $220 million in up-front and milestone payments to PharmaEngine for overseas marketing rights. PharmaEngine, the drug's collaborator, will retain rights in its home country of Taiwan.

2. Secondary drug
MM-121 is involved  in three phase 2 trials, one phase 1/2 trial, and four phase 1 trials. Those trials include several types of cancers such as breast and lung. It is an ambitious drug for a small company but benefits from having Sanofi as a backer.

Sanofi made a $60 million  up-front payment and a series of milestone payments for its share of MM-121. More milestones and potential royalty payments could follow. Sanofi is responsible for the manufacturing and development costs. Merrimack will participate through phase 2 and has the option to co-promote the drug in the U.S. upon its release.

3. Cash burn
Merrimack's cash burn for the most recent quarter was around $21 million . The company reported about $87 million  in cash, cash equivalents, and short-term investments. Combine that with a new loan agreement with a $40 million limit, and Merrimack can probably sustain itself until 2014, when revenues should start flowing.

Final thoughts
It will be some time before late-stage trials report and show a clearer picture of Merrimack's standing. MM-398 will need to show strength in a market that's becoming increasingly crowded. MM-121 could become the underdog champion, especially with Sanofi's contribution. It might benefit investors to take a "wait and see" approach with Merrimack until more data arrives.

Want a closer look at one of Merrimack's potential competitors? With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 31, 2012, at 10:31 AM, kurtdabear wrote:

    If you think this company will be profitable by 2014, you're not a pharmaceutical investor. Everything costs twice as much as estimated and takes twice as long as projected, unless the government changes the rules of the game or makes you repeat a trial, in which case it becomes four times as much and four times as long. Drugs in Phase 2 trials are like minnows in a pool of piranha: Their survival rate is very low.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2170453, ~/Articles/ArticleHandler.aspx, 12/19/2014 11:38:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement